Improved Outcomes When Antibiotic Prescribing Guidelines Are Followed by Healthcare Providers: A Colombian Example to Encourage Adherence in Hospital Settings

Feinstein, Max M.; Escandón-Vargas, Kevin; Reyes, Sergio; Hernández-Gómez, Cristhian; Pallares, Christian; Villegas, María Virginia

doi:10.1017/ice.2017.45

Cited by 9 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Artículo de libre acceso para uso personal e individual. DOI: 10.37980/im.journal.rmdp.20211756 ISSN: 2412642X 33 de atención, en el grupo que fue adherente al flujograma de tratamiento [11].…”

Section: Nac: Neumonía Adquirida En La Comunidad; Capo: Community Acquired Pneumonia Organization Rpcr: Reacción Rápida En Cadena De Poliunclassified

Intervenciones en infecciones del tracto urinario, neumonías, COVID-19 y bacteriemias por programas de uso optimizado de antimicrobianos (PROA): enfoque síndrome específico

Rodríguez

Gundacker

2021

Rev Med Panama

View full text Add to dashboard Cite

Introducción: El uso de los antibióticos ha logrado curar infecciones anteriormente letales. Como profilaxis ha mejorado el pronóstico de pacientes en múltiples escenarios; sin embargo, estos fármacos tienen efectos adversos los cuales pueden ocurrir en 1 de cada 5 pacientes hospitalizados que los reciben, algunos de estos eventos son potencialmente mortales. Los programas de Antimicrobial Stewardship (ASP), conocidos en español como Programas de Uso Optimizado de Antibióticos (PROA), son intervenciones coordinadas, diseñadas para mejorar y medir el uso apropiado de antibióticos, promoviendo la selección del régimen óptimo, incluyendo dosis, duración de la terapia y su ruta de administración. Objetivo: describir el beneficio de las intervenciones síndrome específico en infecciones del tracto urinario, neumonías, bacteriemias y COVID-19, realizadas por programas de uso optimizado de antimicrobianos (PROA). Metodología: se realizó una búsqueda en PubMed y se seleccionó aquellos artículos donde se realizaron intervenciones que mostraron beneficios clínicos en infecciones del tracto urinario, neumonías, bacteriemias y COVID-19 por parte de programas de uso optimizado de antimicrobianos. Síntesis de los datos: se seleccionaron 18 estudios, de los cuales 3 mostraron intervenciones con beneficios en el tratamiento de Infecciones del tracto urinario, 9 en neumonías, 1 en COVID-19 y 5 en bacteriemias. Conclusión: Las intervenciones síndrome específicas, en Infecciones del tracto urinario (ITU), neumonías COVID-19 y bacteriemias, de los programas de uso optimizado de antibióticos (PROA) se han asociado con disminución de los costos de atención y mejores resultados clínicos.

show abstract

Section: Nac: Neumonía Adquirida En La Comunidad; Capo: Community Acquired Pneumonia Organization Rpcr: Reacción Rápida En Cadena De Poliunclassified

Intervenciones en infecciones del tracto urinario, neumonías, COVID-19 y bacteriemias por programas de uso optimizado de antimicrobianos (PROA): enfoque síndrome específico

Rodríguez

Gundacker

2021

Rev Med Panama

View full text Add to dashboard Cite

show abstract

“…Another approach is to work with a partner organization to establish a regional AMS Center of Excellence, which then provides AMS implementation support to institutions across the specific region. Recently published data from a partnership with the independent, nonprofit research institute CIDEIM show that the establishment of such regional centers results in improved adherence to antibiotic prescribing guidelines, reduced resistance rates, and healthcare cost savings [ 6 , 7 ]. So far as part of this initiative, more than 10 000 healthcare providers have been trained by company-employed medical science liaisons (MSLs) and/or external scientific experts, and over 500 locally tailored clinical treatment pathways have been implemented.…”

Section: What Specific Actions Can Pharmaceutical Companies Take To Smentioning

confidence: 99%

The Role of Pharmaceutical Companies in Antimicrobial Stewardship: A Case Study

Hermsen

Sibbel

Holland

2020

Clinical Infectious Diseases

View full text Add to dashboard Cite

Rising levels of antimicrobial resistance pose serious dangers to patients, population health, food security, and economic stability worldwide. In response to this threat, the United Nations and the World Health Organization have called for multisectoral, multidisciplinary action, recognizing that human, animal, and environmental health are interdependent. Although the pharmaceutical industry clearly has a leading role in developing novel antimicrobials and vaccines, it is also active in many areas supporting antimicrobial stewardship. This article describes why pharmaceutical companies invest in antimicrobial stewardship, outlines why they are well suited to help address this issue, and provides examples of how the pharmaceutical industry can support the responsible use of antimicrobials. Merck & Co., Inc. (Kenilworth, NJ, USA), a large, globally operating pharmaceutical company that develops and markets both human and veterinary antimicrobials and vaccines is used as a case study for illustrating industry involvement in antimicrobial stewardship efforts.

show abstract

“…Selection of resistant P. aeruginosa during imipenem therapy is substantially more frequent than selection of ciprofloxacin-, piperacillin- and ceftazidime-resistant mutants, and increases the risk of intestinal colonization by resistant clones [ 16 , 17 ]. She added that in her hospital, adherence to local carbapenem-sparing antimicrobial guidelines reduced the risk of severe sepsis and other clinical complications in patients with complicated UTI [ 18 ].…”

Section: Antimicrobial Stewardship: Strategic Approachesmentioning

confidence: 99%

Gram-Negative Infections: Evolving Treatments With Expanding Options

Villegas

Lyon²

2018

Future Sci. OA

View full text Add to dashboard Cite

Antibiotic resistance was a major topic of interest for the nearly 13,000 physicians, microbiologists and scientists who attended European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2018. Much discussion centered round the potential benefits of novel antibiotics that are either already approved or under investigation in the treatment of infections caused by resistant Gram-negative pathogens. There was also general acceptance of the importance of ensuring that antibiotic stewardship is implemented in every ward throughout every hospital to ensure that these novel drugs are used appropriately and to combat the development of resistance.

show abstract

Improved Outcomes When Antibiotic Prescribing Guidelines Are Followed by Healthcare Providers: A Colombian Example to Encourage Adherence in Hospital Settings

Cited by 9 publications

References 11 publications

Intervenciones en infecciones del tracto urinario, neumonías, COVID-19 y bacteriemias por programas de uso optimizado de antimicrobianos (PROA): enfoque síndrome específico

Intervenciones en infecciones del tracto urinario, neumonías, COVID-19 y bacteriemias por programas de uso optimizado de antimicrobianos (PROA): enfoque síndrome específico

The Role of Pharmaceutical Companies in Antimicrobial Stewardship: A Case Study

Gram-Negative Infections: Evolving Treatments With Expanding Options

Contact Info

Product

Resources

About